The use of remote patient monitoring (RPM) and decentralised clinical trials (DCTs) have surged as the industry started using these strategies to tackle the COVID-19-induced clinical trial disruptions.

GlobalData conducted a survey to identify how the pharmaceutical and healthcare industry is addressing clinical trial disruptions amid the pandemic.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Remote patient monitoring and decentralised clinical trials emerge as dominant strategies to counter clinical trial disruptions

Addressing Clinical Trial Disruptions Related to the COVID-19 Outbreak

According to the survey results, 17% of the respondents adopted RPM to address clinical trial disruptions, while another 15% intend to switch to DCTs.

Approximately 14% voted for remote site initiation visits, while 13% of the companies asked research staff to work remotely.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Direct-to-patient (DTP) drug delivery was selected by 11% of the respondents.

Among the respondents, 9% halted screening and/ or enrolment for all clinical trials due to the pandemic situation and another 7% completely ceased opening any new trials.

Around 7% of the surveyed companies prioritised enrolment for certain clinical trials.

The remaining 7% respondents implemented remote safety lab collections.

The analysis is based on responses received for the Coronavirus Disease 2019 (COVID-19) Sector Impact: The COVID-19 Pandemic Impact on Clinical Trials survey conducted by GlobalData between 04 June and 22 June 2020.